STOCK TITAN

Gain Therapeutics: rexaceract motor scores stable

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Gain Therapeutics, Inc. reported 12-month Phase 1b results for rexaceract: all 13 evaluable participants completed the 12-month administration, including the three-month initial study and nine-month open-label extension. MDS-UPDRS motor scores were stable compared with baseline, with no overall disease progression measured by Parts II and III among those participants.

After 90 days, all 11 evaluable patients with Parkinson’s disease who had evaluable cerebrospinal fluid samples had reduced or unchanged CSF GluSph from baseline. A participant later diagnosed with multiple system atrophy showed a change in GluSph in the opposite direction and no meaningful clinical response. The company said rexaceract was generally well tolerated over 12 months; no new safety concerns arose in Part 2 reviews, Treatment-Emergent Adverse Events had a lower incidence in Part 2 than Part 1, and no new clinically relevant liver enzyme elevations were observed with continued dosing for up to one year.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Evaluable participants completing treatment 13 participants Completed 12 months of rexaceract administration
Treatment period 12 months Full administration period completed by the 13 evaluable participants
Parkinson’s disease patients with evaluable CSF samples 11 patients Biomarker results reported after the first 90 days of dosing
Initial dosing period 3 months (90 days) Period after which CSF GluSph findings were reported
Open-label extension 9 months Part 2 of the Phase 1b study
Phase 1b clinical study medical
"data from the Phase 1b clinical study of rexaceract"
MDS-UPDRS Parts II and III scales medical
"measured by the MDS-UPDRS Parts II and III scales"
cerebrospinal fluid (CSF) medical
"evaluable cerebrospinal fluid (CSF) samples"
Cerebrospinal fluid (CSF) is a clear liquid that surrounds and cushions the brain and spinal cord, providing protection and helping to remove waste. Although it is a medical term, in a financial context, understanding how resources and support flow within a system can be similar to how CSF circulates and maintains the health of the nervous system. Recognizing such fundamental processes can offer insights into the stability and resilience of broader systems, including financial markets.
glucosylsphingosine (GluSph) medical
"CSF glucosylsphingosine (GluSph) levels"
A small molecule found in blood and other tissues that increases when the body cannot properly break down certain fats; clinicians and researchers measure it as a biological marker of disease activity. For investors it matters because changes in this marker can show whether a drug or treatment is working, help speed diagnosis, guide regulatory decisions, and influence the commercial value of therapies — like a car’s check‑engine light signaling when repairs or improvements make a real difference.
open-label extension medical
"the 9-month open-label extension"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
Treatment-Emergent Adverse Events (TEAEs) medical
"incidence of Treatment-Emergent Adverse Events (TEAEs)"
Adverse events that first appear or worsen after a patient starts a medical treatment; they are the new or intensified negative effects linked in time to taking the drug or therapy. Investors care because the number and severity of these events shape regulators’ decisions, drug labeling, patient uptake and potential legal or cost risks—think of them like customer complaints that can slow sales, trigger recalls, or change a product’s value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GANX report from rexaceract’s 12-month Phase 1b study?

All 13 evaluable participants completed 12 months of rexaceract administration. MDS-UPDRS motor scores were stable compared with baseline, with no overall disease progression measured by Parts II and III among those participants.

What happened to CSF GluSph in GANX’s rexaceract study?

After 90 days, all 11 evaluable patients with Parkinson’s disease who had evaluable CSF samples showed reduced or unchanged GluSph levels from baseline. A participant later diagnosed with multiple system atrophy showed a change in the opposite direction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001819411 0001819411 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

     
Gain Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40237   85-1726410
(State or Other Jurisdiction
of Incorporation)
  (Commission File
Number)
  (I.R.S. Employer
Identification No.)

 

4800 Montgomery Lane, Suite 220

Bethesda, Maryland 20814

(Address of principal executive offices, including zip code)

 

(301) 500-1556

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class: Trading Symbol

Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share GANX The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On November 17, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of clinical data from the Phase 1b clinical study of rexaceract. As of November 1, 2026, all 13 evaluable patients in the Phase 1b clinical study have completed the full 12-month administration of rexaceract, comprising the 3-month Part 1 of the study and the 9-month open-label extension. MDS-UPDRS motor scores demonstrated stability when compared to baseline with no overall disease progression as measured by the MDS-UPDRS Parts II and III scales among the 13 evaluable participants who had completed 12 months of daily oral administration of rexaceract. Following the first 3 months (90 days) of dosing, all 11 evaluable patients with Parkinson's disease, and from whom the Company had evaluable cerebrospinal fluid (CSF) samples, demonstrated reductions or no change in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) levels from baseline. One participant was subsequently diagnosed with multiple system atrophy (MSA). This participant demonstrated a change in CSF GluSph in the opposite direction. This participant also did not demonstrate a meaningful clinical response to treatment.

 

Long-term data demonstrated that rexaceract is generally well tolerated over 12 months of dosing. No new safety concerns were identified during Part 2 (the 9-month extension) Data Monitoring Committee reviews and overall, a lower incidence of Treatment-Emergent Adverse Events (TEAEs) occurred in Part 2 of the study compared with Part 1 (initial three-month administration). Additionally, no new clinically relevant liver enzyme elevations were observed with continued dosing for up to 1 year.

 

 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GAIN THERAPEUTICS, INC.
   
Dated: November 17, 2026 By: /s/ Gene Mack
    Gene Mack
    Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading